Economic situation of apiary farms running Polish accounting FADN in 2009

W artykule przedstawiono wyniki produkcyjno-ekonomiczne gospodarstw objętych badaniami Polskiego FADN i zajmujących się przede wszystkim produkcją miodu i innych produktów pasiecznych w 2009 roku. Liczba badanych gospodarstw była niewielka (28). Omówione w artykule gospodarstwa były typowymi gospodarstwami rodzinnymi o niewielkiej powierzchni użytków rolnych (średnio 3,3 ha). Na analizowane gospodarstwo przypadało średnio 170 rodzin pszczelich, a wydajność rodziny pszczelej wynosiła 19,5 kg miodu. Dochód z takiego gospodarstwa w przeliczeniu na 1 osobę pracującą w rodzinie rolnika był w 2009 roku wyższy o 15,1 % niż średnie wynagrodzenie netto w gospodarce narodowej. Przedstawione wyniki mogą być zachętą do powiększania małych pasiek lub zakładania nowych.The article presents the production and economic results of farms covered by the Polish FADN research and dealing mainly with the production of honey and other apiary products in 2009. The number of researched farms was small (28). The farms discussed in the article were typical family farms with a small agricultural area (3.3 ha on average). There were on average 170 bee colonies per the analyzed farm, and the colony productivity was 19.5 kg of honey. The income from such a farm per 1 person working in the farmer's family was in 2009 higher by 15.1% than the average net salary in the national economy. The presented results can be an incentive to enlarge small apiaries or establish new ones

The prevalence of SARS-CoV-2 infection and the severity of the course of COVID-19 in patients with psoriasis treated with biologic therapy

Background Biologics are used for the treatment of patients with moderate to severe psoriasis. According to the recommendations of major global dermatological associations, patients who had not reported clinical symptoms or close contact with a confirmed/probable COVID-19 case in the last 14 days can continue biologic therapy. Objective The aim of our study was to determine the prevalence of SARS-CoV-2 infection, its clinical manifestations and the influence of COVID-19 on the course of the underlying disease in patients with moderate to severe psoriasis and aggressive psoriatic arthritis undergoing biologic therapy. Material and methods All 61 patients with moderate to severe psoriasis treated with biologics in the Dermatology Department of Central Clinical Hospital of Ministry of the Interior and Administration in Warsaw were enrolled into the study. Firstly, the medical histories of these patients were assessed for occurrence of severe adverse events, COVID-19 symptoms and deaths. Afterwards, the prevalence of serum anti-SARS-CoV-2 antibodies, and severity of COVID-19 were assessed. Results Ten patients in the study group have developed anti-SARS-CoV-2 antibodies. One patient presented with mild COVID-19 symptoms. Conclusion While our study had a small sample size, ongoing biologic treatment in psoriasis was not associated with severe form of COVID-19